Stock CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:02 2024-09-17 pm EDT 		5-day change 1st Jan Change
206.21 USD +1.22% Intraday chart for Charles River Laboratories International, Inc. +8.52% -12.77%
Sep. 17 Charles River Laboratories, CEBINA Partner to Accelerate Neurodegenerative Drug Development MT
Sep. 10 Transcript : Charles River Laboratories International, Inc. Presents at Baird's 2024 Global Healthcare Conference, Sep-10-2024 10:15 AM

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Charles River Laboratories, CEBINA Partner to Accelerate Neurodegenerative Drug Development
MT
Charles River Laboratories, Insightec Collaborate on Focused Ultrasound in Neuroscience
MT
Charles River Laboratories International, Inc. and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
CI
Charles River cuts 2024 forecast on lower demand for drug development services
RE
Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on July 29, 2010.
CI
Charles River Laboratories International to Seeks Strategic Acquisitions
CI
Charles River cuts 2024 forecast as funding crunch among biotech clients persists
RE
Charles River Laboratories' Q2 Non-GAAP Earnings Rise, Revenue Falls; 2024 Outlook Slashed
MT
(CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Sees Fiscal Year 2024 EPS Range $9.90 - $10.20
MT
Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Reports Q2 Revenue $1.03B, vs. Street Est of $1.02B
MT
Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Reports Q2 EPS $2.80, vs. Street Est of $2.39
MT
Charles River Laboratories International, Inc. announces an Equity Buyback for $1,000 million worth of its shares.
CI
Charles River Laboratories International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 29, 2024
CI
Charles River Laboratories International, Inc. Revises Earnings Guidance for the Year 2024
CI
Charles River Laboratories International, Inc's Equity Buyback announced on July 29, 2010, has expired.
CI
Charles River Laboratories International, Inc. authorizes a Buyback Plan.
CI
Charles River Laboratories International, Inc. Collaborates with Foxg1 Research Foundation to Advance Rare Disease Gene Therapy Development
CI
Charles River Laboratories Invests in Autobahn Labs Under Collaborative Deal
MT
Charles River Laboratories International, Inc. and AAVantgarde Announces Contract Development and Manufacturing Organization Agreement to Produce Good Manufacturing Practice
CI
Charles River Laboratories, Gates Institute Collaborate on Lentiviral Vector Manufacturing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRL Stock
  4. News Charles River Laboratories International, Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW